Bellicum Pharmaceuticals, Inc. is a clinical stage company developing next generation therapeutic vaccines for the treatment of cancer and infectious diseases. The company’s pharmacologically regulated DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific TH1 immune response. Our lead product, BPX-101, an autologous DeCIDe™ vaccine, is in Phase I clinical trials for patients with metastatic castrate resistant prostate cancer (mCRPC).